Pear Therapeutics, Inc.
NASDAQ: PEAR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Christopher D. T. Guiffre MBA
- Employees
- 200
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $4.1M
- Website
- https://peartherapeutics.com
Loading PEAR…
Loading profile data…Frequently asked questions about PEAR
What does Pear Therapeutics, Inc. (PEAR) do?
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital so...
Where does PEAR trade?
Pear Therapeutics, Inc. (PEAR) trades on the NASDAQ Capital Market.
What sector is PEAR in?
Pear Therapeutics, Inc. (PEAR) operates in the Healthcare sector, specifically in the Medical - Healthcare Information Services industry.
Who is the CEO of Pear Therapeutics, Inc.?
Christopher D. T. Guiffre MBA is the chief executive officer of Pear Therapeutics, Inc. (PEAR).
Where is Pear Therapeutics, Inc. headquartered?
Pear Therapeutics, Inc. is headquartered in United States.
Does PEAR pay a dividend?
Pear Therapeutics, Inc. (PEAR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PEAR go public?
Pear Therapeutics, Inc. (PEAR) completed its initial public offering in 2021.